CSG/TELENOR-DENMARK
23.7.2024 08:31:33 CEST | Business Wire | Press release
Telenor Denmark, the second-largest mobile operator in the Danish market, is a trailblazer for customer-first innovation. To reinforce its position at the forefront of digital telecommunications commerce and continue to provide excellent customer experiences, Telenor Denmark chose CSG®‘s (NASDAQ: CSGS) cloud-native, software-as-a-service (SaaS) platforms to drive its evolution into the future. This transformation turbocharges Telenor Denmark’s omnichannel monetisation, improves business efficiency and future-proofs the B2C and B2B customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722892898/en/
“At Telenor Denmark, we make it easy for our 1.7 million customers to connect with the people and services that matter most to them. This is how we earned the industry’s highest customer satisfaction in 2023,” said Lars Thomsen, CEO, Telenor Denmark. “As we look to the future, we must adapt to meet fluctuating demands and continue to offer new, innovative solutions to our customers. CSG has the proven track record, industry depth and cloud expertise we need to embrace end-to-end digitalisation that will further strengthen our ability to deliver excellent customer service and inspire our customers. It’s an exciting time for Telenor Denmark and this strategic collaboration with CSG brings us one step closer to the future we want to shape for our customers, partners and ourselves.”
As Telenor Denmark and CSG collaborate to make the communication service provider (CSP) a leading digital telco in Denmark, CSG Ascendon, a market-leading AWS cloud-native revenue management platform, with pre-integrated, world-class customer engagement capabilities powered by CSG Xponent, enhance Telenor Denmark’s growth with flexibility, efficiency and intelligence. With CSG’s real-time decisioning engine, Telenor Denmark will deliver better digital experiences across all touchpoints, enhance omnichannel support for all business segments and seize new revenue opportunities. Along with CSG’s industry-leading configure, price and quote capabilities, the two platforms give Telenor Denmark powerful tools to seamlessly bundle offers with partners and create faster, more efficient solutions for its business customers. These improvements make it easy for Telenor Denmark to keep happier, more loyal customers that drive faster revenue for future innovation.
“To come out on top in digital telco commerce, CSPs need business infrastructure that allows them to hit the ground running and wow customers with speed, sophistication and flexibility,” said Ian Waterson, SVP of Go-To-Market, CSG. “As a customer satisfaction leader, Telenor Denmark understands the importance of customer loyalty in driving long-term growth. Their trust in CSG and our industry-leading solutions will elevate customer experience and set Telenor Denmark up for future-ready success.”
Get the facts on CSG Ascendon’s B2C, B2B and B2B2X capabilities and read CSG’s eBook to discover how you can make your CX more proactive, predictive and personalised with data-driven customer communication programs.
About CSG
CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.
Want to be future-ready and a change-maker like the global brands that trust CSG? Visit csgi.com to learn more.
About Telenor Denmark
Telenor helps Danes create good connections through mobile and internet services. We are committed to being the telecommunications company that provides Danish businesses and consumers with a secure, straightforward, and safe digital everyday life. Therefore, we invest massively in innovation and in developing the Danish telecommunications infrastructure and have recently completed the 5G modernization of our nationwide mobile network.
Telenor is Denmark's second-largest mobile operator and a part of the Telenor Group, operating throughout Scandinavia and Asia. Globally, we assist 186 million customers in their communication needs. In Denmark, we have approximately 1000 employees and 38 stores spread across the country.
You can learn more about us at www.telenor.dk.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722892898/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom